IMMUCELL CORP /DE/(ICCC)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #628 of 2,879 stocksTOP 25%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
ICCC Stock Analysis & AI Quality Score
AI stock analysis and institutional research for IMMUCELL CORP /DE/ (ICCC), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ICCC at 64.6/100 on a 32-signal composite quality model, placing it at rank #628 of 2,879 stocks — the top 25% of the AI-ranked universe. ICCC scores in the top quartile across revenue growth (85.0), balance sheet strength (84.2), profitability (80.0). Areas of concern include revenue scale (7.5) and earnings quality (30.0), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q1 2026), IMMUCELL CORP /DE/ reports quarterly revenue of $10.4M, net income of $1.9M, free cash flow of $3.4M. Top institutional holders of ICCC by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, MORGAN STANLEY, RENAISSANCE TECHNOLOGIES, based on the most recent SEC filings. ICCC trades on the Nasdaq exchange and files with the SEC under CIK 811641. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ICCC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for IMMUCELL CORP /DE/ directly from SEC EDGAR.
Revenue
Q1 2026
$10.4M
Net Income
Q1 2026
$1.9M
Free Cash Flow
Q1 2026
$3.4M
D/E Ratio
Q1 2026
0.35
Get alerted when ICCC's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for IMMUCELL CORP /DE/ including:
Top Institutional Holders of ICCC
VANGUARD CAPITAL MANAGEMENT LLC
$1.6M260,327 shMORGAN STANLEY
$1.4M221,716 shRENAISSANCE TECHNOLOGIES LLC
$960.8K151,789 shCresset Asset Management, LLC
$856.2K135,267 shBleichroeder LP
$643.1K101,594 shGEODE CAPITAL MANAGEMENT, LLC
$416.4K65,765 shDIMENSIONAL FUND ADVISORS LP
$354.7K56,030 shSteadtrust LLC
$344.2K54,370 shVANGUARD FIDUCIARY TRUST CO
$270.1K42,669 shMesirow Financial Investment Management, Inc.
$268.9K42,481 sh
| Fund | Value | Shares |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $1.6M | 260,327 |
| MORGAN STANLEY | $1.4M | 221,716 |
| RENAISSANCE TECHNOLOGIES LLC | $960.8K | 151,789 |
| Cresset Asset Management, LLC | $856.2K | 135,267 |
| Bleichroeder LP | $643.1K | 101,594 |
| GEODE CAPITAL MANAGEMENT, LLC | $416.4K | 65,765 |
| DIMENSIONAL FUND ADVISORS LP | $354.7K | 56,030 |
| Steadtrust LLC | $344.2K | 54,370 |
| VANGUARD FIDUCIARY TRUST CO | $270.1K | 42,669 |
| Mesirow Financial Investment Management, Inc. | $268.9K | 42,481 |
More Healthcare Companies
View all Healthcare →Put ICCC on your watchlist
Track score changes the day IMMUCELL CORP /DE/ files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ICCC a good stock to buy?
13F Pro's AI-powered analysis of IMMUCELL CORP /DE/ (ICCC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ICCC are available on the ICCC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own ICCC?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ICCC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of IMMUCELL CORP /DE/'s investment landscape.